Your browser doesn't support javascript.
loading
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Chan, Arlene; Moy, Beverly; Mansi, Janine; Ejlertsen, Bent; Holmes, Frankie Ann; Chia, Stephen; Iwata, Hiroji; Gnant, Michael; Loibl, Sibylle; Barrios, Carlos H; Somali, Isil; Smichkoska, Snezhana; Martinez, Noelia; Alonso, Mirta Garcia; Link, John S; Mayer, Ingrid A; Cold, Søren; Murillo, Serafin Morales; Senecal, Francis; Inoue, Kenichi; Ruiz-Borrego, Manuel; Hui, Rina; Denduluri, Neelima; Patt, Debra; Rugo, Hope S; Johnston, Stephen R D; Bryce, Richard; Zhang, Bo; Xu, Feng; Wong, Alvin; Martin, Miguel.
Afiliação
  • Chan A; Breast Clinical Trials Unit, Breast Cancer Research Centre-WA & Curtin University, Perth, Australia. Electronic address: arlenechan@me.com.
  • Moy B; Breast Oncology Program, Massachusetts General Hospital Cancer Center, Boston, MA.
  • Mansi J; Oncology & Haematology Clinical Trials, Guy's and St Thomas Hospital NHS Foundation Trust and Biomedical Research Centre, King's College, London, United Kingdom.
  • Ejlertsen B; Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
  • Holmes FA; Texas Oncology/US Oncology Research, Houston, TX.
  • Chia S; Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada.
  • Iwata H; Clinical Oncology, Aichi Cancer Center, Chikusa-ku, Nagoya, Japan.
  • Gnant M; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Loibl S; Center for Hematology and Oncology Bethanien, Frankfurt, Germany.
  • Barrios CH; Centro de Pesquisa em Oncologia, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil.
  • Somali I; Department of Oncology, Dokuz Eylul Universitesi Tip Fakultesi Hastanesi Tibbi Onkoloji Anabilim Dali Mithatpasa, Balçova, Izmir, Turkey.
  • Smichkoska S; University Clinic for Radiotherapy and Oncology, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia.
  • Martinez N; Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Alonso MG; Oncología Médica, Hospital Universitario Nuestra Señora de la Candelaria Ctra. Del Rosario, Sta. Cruz De Tenerife, Canarias.
  • Link JS; Breastlink Medical Group, Inc, Santa Ana, CA.
  • Mayer IA; Division of Hematology/Oncology, Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Nashville, TN.
  • Cold S; Onkologisk Afdeling R, Odense University Hospital, Odense, Denmark.
  • Murillo SM; Hospital Universitario Arnau Vilanova Servei d'Oncologia Mèdica i Hematologia, Lleida, Spain.
  • Senecal F; Physician Medical Center, Northwest Medical Specialties PLLC, Tacoma, WA.
  • Inoue K; Breast Oncology, Saitama Cancer Center, Kita-Adachi, Japan.
  • Ruiz-Borrego M; Oncología, Hospital Universitario Virgen del Rocio, Seville, Spain.
  • Hui R; Crown Princess Mary Cancer Centre, Westmead Hospital and University of Sydney, Sydney, NSW, Australia.
  • Denduluri N; Virginia Cancer Specialists, Arlington, VA.
  • Patt D; Texas Oncology - Round Rock, Austin, TX.
  • Rugo HS; Department of Medicine (Hematology/Oncology), University of California San Francisco Comprehensive Cancer Center, San Francisco, CA.
  • Johnston SRD; The Breast Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Bryce R; Puma Biotechnology Inc., Los Angeles, CA.
  • Zhang B; Puma Biotechnology Inc., Los Angeles, CA.
  • Xu F; Puma Biotechnology Inc., Los Angeles, CA.
  • Wong A; Puma Biotechnology Inc., Los Angeles, CA.
  • Martin M; Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain.
Clin Breast Cancer ; 21(1): 80-91.e7, 2021 02.
Article em En | MEDLINE | ID: mdl-33183970

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinolinas / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinolinas / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 Idioma: En Ano de publicação: 2021 Tipo de documento: Article